Molecular Diagnostics Publications

T-cell leukemia/lymphoma

Hosler GA, Liégeois NJ, Anhalt GJ, Moresi JM. Transformation of cutaneous gamma/delta T-cell lymphoma following fifteen years of indolent behavior. J Cutan Pathol 2008;35:1063-1067.

Hosler GA, Bash RO and Scheuermann RH. Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T-cell acute lymphoblastic leukemia. Leukemia 2000;14:1215-1224.

Hosler GA, Bash RO, Bai X, Jain V and Scheuermann RH. Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma. Am J Pathol 1999;154:1023-1035

Berg KD, Brinster NK, Huhn KM, Goggins MG, Jones RJ, Makary A, Murphy KM, Griffin CA, Rosenblum-Vos LS, Borowitz MJ, Nousari HC, Eshleman JR: Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. N Engl J Med 2001, 345:1458-63

Batista DA, Vonderheid EC, Hawkins A, Morsberger L, Long P, Murphy KM, Griffin CA: Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sezary syndrome: search for recurrent chromosome abnormalities. Genes Chromosomes Cancer 2006, 45:383-91

 

Acute Myelogenous Leukemia (AML)/FLT3

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD: Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003, 5:96-102

Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan RH, Borowitz MJ, Berg KD, Murphy KM: FLT3 mutations in myeloid sarcoma. Br J Haematol 2004, 126:785-91

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-76

Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, McNiece I, Smith BD, Small D: Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005, 106:673-80

Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010 Feb 18;115(7):1425-32.

 

Chronic Myelogenous Leukemia (CML)/BCR-ABL

Jinawath N, Norris-Kirby A, Smith BD, Gocke CD, Batista DA, Griffin CA, and Murphy KM.  A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.J Mol Diagn. 2009 Jul;11(4):359-63.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy KM, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-47

Batista DA, Hawkins A, Murphy KM, Griffin CA: BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present. Cancer Genet Cytogenet 2005, 163:164-7

 

Gliomas

Peaston AE, Gardaneh M, Franco AV, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB, Marshall GM: MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 2001, 85:1564-71

Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM, Berg KD: Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 2003, 83:419-28

Wang M, Murphy KM, Kulesza P, Hatanpaa KJ, Olivi A, Tufaro A, Erozan Y, Westra WH, Burger PC, Berg KD: Molecular diagnosis of metastasizing oligodendroglioma: a case report. J Mol Diagn 2004, 6:52-7

Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL: Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005, 102:14344-9

Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM: Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65:988-94

 

Colorectal Cancer

Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, Yeo CJ, Hruban RH, Kern SE: Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res 2003, 63:994-9

Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR: Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006, 8:305-11

Tsiatis AC, Kirby AN, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, and Murphy KM.  Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve analysis for the detection of KRAS Mutations: Diagnostic and Clinical Implications J Mol Diagn. 2010 Jul;12(4):425-32.

 

Pancreatic  Carcinoma

Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, Kern SE: ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A 2001, 98:3254-7

Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-93

Cao D, Hustinx SR, Sui G, Bala P, Sato N, Martin S, Maitra A, Murphy KM, Cameron JL, Yeo CJ, Kern SE, Goggins M, Pandey A, Hruban RH: Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther 2004, 3:1081-9; discussion 1090-1

Rogers CD, Couch FJ, Brune K, Martin ST, Philips J, Murphy KM, Petersen G, Yeo CJ, Hruban RH, Goggins M: Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004, 41:e126

Karanjawala ZE, Illei P, Ashfaq R, Infante J, Murphy KM, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban R: New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. Am J Surg Pathol. 2008, 32 2:188-96

 

Thyroid Carcimona

Rosenbaum E, Hosler GA, Zahurak M, Cohen Y, Sidransky D and Westra WH. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 2005;18:898-902.

Murphy KM, Chen F, Clark DP. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol. 2008, 39 3:420-6

Murphy KM, Chen F, Clark DP. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol. 2008, 39 3:420-6

 

Identity Testing In The Clinical Lab

Berg KD and Murphy KM: “Floaters” in Surgical Pathology Tissues: Genetic Identity Testing Potential and Pitfalls. Pathol Case Rev 2003, 8:3103-10

Cao D, Hafez M, Berg K, Murphy KM, Epstein JI: Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity. Am J Surg Pathol 2005, 29:467-73

 

Books

Hosler GA, Murphy KM.  Molecular Diagnostics for Dermatology:  Practical applications of current molecular testing for the diagnosis and management of the dermatology patient. Springer 2014 (in press)